Co-Occurrence CDK4/6 Amplification Serves as Biomarkers of De Novo EGFR TKI Resistance in Sensitizing EGFR Mutation Non-Small Cell Lung Cancer

Scientists explored clinical factors in 332 advanced NSCLC who received EGFR TKI and molecular characteristics through 65 whole exome sequencing of various EGFR TKI responses including; de novo, intermediate response and long-term response.